Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000785909
Ethics application status
Approved
Date submitted
27/07/2011
Date registered
27/07/2011
Date last updated
15/05/2014
Type of registration
Retrospectively registered

Titles & IDs
Public title
Cardiovascular Magnetic Resonance Imaging study assessing myocardial ischemia in patients with end-stage renal disease and renal transplant - End Stage Renal Disease cohort
Scientific title
Study of myocardial ischemia post renal transplant as assessed by Cardiac MRI in patients with end-stage renal disease - End Stage Renal Disease cohort
Secondary ID [1] 262719 0
nil
Universal Trial Number (UTN)
U1111-1122-1549
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
myocardial ischaemia in end stage renal disease patients 270427 0
Condition category
Condition code
Cardiovascular 270569 270569 0 0
Coronary heart disease
Renal and Urogenital 270570 270570 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Framingham's risk score at baseline (race, age, smoking history, family history of cardiac disease, cardiac risk factors)
Blood tests at baseline - biochemical markers (hsCRP); markers of fibrosis (MMP); troponin T, BNP and homocysteine levels.
Cardiac MRI at baseline - cine images; Blood oxygen level dependent MRI (BOLD) rest and stress using adenosine 140mcg/kg/min for 3-6 minutes
Clinic visit at 12 months for repeat bloods. Phone follow up at 24 months
Intervention code [1] 267064 0
Diagnosis / Prognosis
Comparator / control treatment
nil
Control group
Uncontrolled

Outcomes
Primary outcome [1] 269313 0
Major Adverse Cardiac Events including angina, myocardial infarction, rehospitalisation with cardiac event, cerebrovascular event, heart failure and death assessed by reviewing patients medical records and phone call
Timepoint [1] 269313 0
6, 12 and 24 months
Secondary outcome [1] 279357 0
BOLD-CMR as predictors of Major Adverse Cardiac Events
Timepoint [1] 279357 0
6, 12 and 24 months
Secondary outcome [2] 279358 0
Troponin T and hsCRP as predictors of Major Adverse Cardiac Events
Timepoint [2] 279358 0
6, 12 and 24 months

Eligibility
Key inclusion criteria
Patients with end-stage renal disease on haemodialysis or peritoneal dialysis and or GFR 30-60ml/min
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Known history of coronary artery disease, inability to give informed consent, extreme claustrophobia, implantable cardiac devices and other contra-indications to MRI, asthma or other reversible bronchospasm, patients on theophylline, inability to lie flat for 1 hour

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
1/07/2011
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
80
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 267539 0
Hospital
Name [1] 267539 0
Flinders Medical Center
Country [1] 267539 0
Australia
Primary sponsor type
Individual
Name
Professor Joseph Selvanayagam
Address
Dept Cardiovascular Medicine
Flinders Medical Centre
1 Flinders Drive
BEDFORD PARK
SA 5042
Country
Australia
Secondary sponsor category [1] 266577 0
None
Name [1] 266577 0
Address [1] 266577 0
Country [1] 266577 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 269494 0
Southern Adelaide Clinical Human Research Ethics Committee
Ethics committee address [1] 269494 0
Ethics committee country [1] 269494 0
Australia
Date submitted for ethics approval [1] 269494 0
02/09/2010
Approval date [1] 269494 0
14/02/2011
Ethics approval number [1] 269494 0
1/10/0380

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 32937 0
Address 32937 0
Country 32937 0
Phone 32937 0
Fax 32937 0
Email 32937 0
Contact person for public queries
Name 16184 0
Christine Edwards
Address 16184 0
Flinders Clinical Research
Level 3A
Mark Oliphant Building
Laffer Drive
BEDFORD PARK
SA 5042
Country 16184 0
Australia
Phone 16184 0
+61 8 8201 5656
Fax 16184 0
Email 16184 0
christine.edwards2@health.sa.gov.au
Contact person for scientific queries
Name 7112 0
Professor Joseph Selvanayagam
Address 7112 0
Dept Cardiovascular Medicine
Flinders Medical Centre
1 Flinders Drive
BEDFORD PARK
SA 5042
Country 7112 0
Australia
Phone 7112 0
+61 8 8404 3971
Fax 7112 0
Email 7112 0
joseph.selva@health.sa.gov.au

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.